Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely?
H.C. Wainwright Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $3
Buy Rating Affirmed for Ovid Therapeutics on Promising Safety Profile and Robust Pipeline Progress
B.Riley Financial Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Cuts Target Price to $3
Oppenheimer Maintains Ovid Therapeutics(OVID.US) With Hold Rating
Oppenheimer Sticks to Their Hold Rating for Ovid Therapeutics (OVID)
BTIG Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5
Promising Neurology Breakthrough: Ovid Therapeutics' OV329 Shows Safety and Efficacy Potential
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate In Animal Eyes in Contrast With Vigabatrin
Express News | Ovid Therapeutics Inc: Phase 1 Trial Evaluating Ov329 in Healthy Volunteers Is on-Track for Completion in Late 2024
Express News | Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating Ov329 Does Not Accumulate in Animal Eyes in Contrast With Vigabatrin
Ovid Therapeutics: Alexander Previously Served as Chief Strategy Officer and Chief Corporate Affairs Officer >OVID
Press Release: Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
Ovid Therapeutics to Present at Upcoming September Investor Conferences
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
Ovid Therapeutics Analyst Ratings
H.C. Wainwright Reaffirms Their Buy Rating on Ovid Therapeutics (OVID)
H.C. Wainwright Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $3
H.C. Wainwright analyst Ram Selvaraju maintains $Ovid Therapeutics(OVID.US)$ with a buy rating, and maintains the target price at $3.According to TipRanks data, the analyst has a success rate of 42.2%
TD Cowen Maintains Ovid Therapeutics(OVID.US) With Buy Rating
TD Cowen analyst Ritu Baral maintains $Ovid Therapeutics(OVID.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.8% and a total average return of 9.1% over the
Wedbush Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Cuts Target Price to $4
Wedbush analyst Laura Chico maintains $Ovid Therapeutics(OVID.US)$ with a buy rating, and adjusts the target price from $8 to $4.According to TipRanks data, the analyst has a success rate of 47.0%